Speaking to pharmaphorum on a recent flying visit to London from Celgene's European HQ in Boudry, Switzerland, Pätsi laid out the company's plans for the next few years. Three approvals in three ...

Bristol-Myers Squibb has agreed a $74 billion deal to merge with Celgene in a deal that will boost its presence in oncology and immunology and make it the fourth-largest drugmaker.

Celgene (Warren, NJ), a developer of chirally pure drugs, agreed on June 30 to purchase gene-regulation firm Signal Pharmaceuticals (San Diego, CA) for $200 million in an all-stock deal.